Genetic Extermination of Cancer Cells.

Context: Targeted cancer therapy has lately been the preferred cancer treatment modality. It is principally based on silencing or downregulating of specific genes responsible for cancer. Extensive exploration in this field has revealed the fact that CD95/CD95 ligand (CD95L), apart from their apoptotic role in killing cancer cells, also plays a non-apoptotic role in tumor advancement. Scientists have discovered that by eliminating CD95/CD95L, there is considerable decrease in tumor growth and invasiveness. Objective: Elimination of CD95/CD95L may offer a novel approach to targeted cancer therapy by suppressing the multiplication of tumor cells and thereby ensuring their death. Materials and methods: Data were obtained and analyzed from electronic database searches of relevant published literatures from PubMed and Google Scholar. Conclusion: Targeting the multiple tumor-promoting activity of CD95/CD95L is a potent treatment modality that can better the prognosis and increase the survival rate of cancer patients. [ABSTRACT FROM AUTHOR]